Clinical Trials

The purpose of this study is to determine visual function in patients with Fuchs Endothelial Corneal Dystrophy (FECD) to understand when in the course of disease patients are affected by compromised vision.

The purpose of this study is to determine how corneal transparency is affected in Fuchs dystrophy, and if a measure of corneal transparency (haze) can help grade the severity of the disease.

The purpose of this study is to test how valid and reliable the new V-FUCHS questionnaire is across a spectrum of Fuchs dystrophy patients.

The purpose of this study is to compare patient-reported visual disability before and after endothelial keratoplasty in patients with Fuchs endothelial corneal dystrophy by comparing scores of the previously designed and validated Visual Function and Corneal Health Status (V-FUCHS) questionnaire. Patient-reported disability will be related to the optical properties of the cornea measured by non-contact imaging methods.

This study will establish a repository of stored blood, corneal endothelial and skin fibroblast samples from people with Fuchs endothelial corneal dystrophy (FECD), including both carriers and noncarriers for the most common genetic association, which is a trinucleotide repeat expansion in the noncoding region of the TCF4 gene.

The goal of this study is to understand when in the course of disease vision-related quality of life becomes impaired, and to determine associations between quality of life and visual and optical factors in the disease.

The purpose of this study is to assess the effectiveness and safety of STN1010904 ophthalmic suspension (0.03%, and 0.1 %), twice daily dosing, when compared to Placebo in subjects diagnosed with Fuchs Endothelial Corneal Dystrophy (FECD). This study will consist of a Screening Period of up to 15 days and an 18-month Double-Masked Treatment Period.

The purpose of this study is to determine changes in corneal thickness and backscatter after first morning eye-opening across a range of fuchs endothelial dystrophy severity, and in healthy corneas. Corneal measurements will be made with a Scheimpflug camera and associated changes in visual acuity and glare (forward scatter) will be determined.

In Fuchs endothelial dystrophy, the function of the inside lining (endothelium) of the cornea is not normal. Determining the function of that layer requires hours of testing and is not convenient in clinical practice. In this study, we will make simple measurements of the cornea and compare those to the function of the inside lining of the cornea with the hope that the simple measurements will predict function. This could allow us to determine the function of the inside lining of the cornea in routine clinical practice in a simple and informative test.

The purpose of this study is to test for a clinical and genetic association between Myotonic Dystrophy Type 1 (DM1) and Fuchs endothelial corneal dystrophy (FECD).

The objectives of this study are to determine if the 1-year graft success rate following DMEK performed with corneas from donors without diabetes is superior to the graft success rate with cornea donors with diabetes, to determine if the 1-year central endothelial cell loss (ECL) following DMEK performed with corneas from donors without diabetes is superior to the central ECL when corneas from donors with diabetes are used, nd to explore the relationship of severity of diabetes in the donor, as measured by eye bank-determined diabetes risk categorization scores, post-mortem hemoglobin A1c (HbA1c), and skin advanced glycation endproducts (AGE) and ...